These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37350750)

  • 1. The serum concentration and activity of DPP4 is positively related with the severity of hyperthyroidism in patients with Graves' disease.
    Chang X; Ding X; Wang J; Cai Q; Wang G; Liu J
    Ann Med; 2023 Dec; 55(1):2226910. PubMed ID: 37350750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of TSH-receptor antibody with the clinical and laboratory parameters in patients with newly diagnosed Graves' hyperthyroidism: experience from a tertiary referral center including a large number of patients with TSH-receptor antibody-negative patients with Graves' hyperthyroidism.
    Zuhur SS; Bilen O; Aggul H; Topcu B; Celikkol A; Elbuken G
    Endokrynol Pol; 2021; 72(1):14-21. PubMed ID: 32944926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic testing for Graves' or non-Graves' hyperthyroidism: A comparison of two thyrotropin receptor antibody immunoassays with thyroid scintigraphy and ultrasonography.
    Scappaticcio L; Trimboli P; Keller F; Imperiali M; Piccardo A; Giovanella L
    Clin Endocrinol (Oxf); 2020 Feb; 92(2):169-178. PubMed ID: 31742747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of an automated TSI bridge immunoassay in the diagnosis of Graves' disease and its relationship to the degree of hyperthyroidism.
    Liu T; Zhang X; Long L; Zhou L; Chen J; Li M; Gao Y; Zhou X; Han X; Ji L
    BMC Endocr Disord; 2022 Aug; 22(1):218. PubMed ID: 36045442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased serum level of IL-7 in patients with active Graves' disease.
    Motylewska E; Nieć M; Siejka A; Komorowski J; Ławnicka H; Świętosławski J; Stępień H
    Cytokine; 2015 Oct; 75(2):373-9. PubMed ID: 26113403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Mediation Role of Thyrotropin Receptor Antibody in the Relationship Between Age and Severity of Hyperthyroidism in Graves' Disease.
    Suzuki N; Inoue K; Yoshimura R; Kinoshita A; Suzuki A; Fukushita M; Matsumoto M; Yoshihara A; Watanabe N; Noh JY; Katoh R; Sugino K; Ito K
    Thyroid; 2022 Oct; 32(10):1243-1248. PubMed ID: 36074931
    [No Abstract]   [Full Text] [Related]  

  • 7. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays.
    Pedersen IB; Knudsen N; Perrild H; Ovesen L; Laurberg P
    Clin Endocrinol (Oxf); 2001 Sep; 55(3):381-90. PubMed ID: 11589682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial dysfunction in children with newly diagnosed Graves' disease.
    Gamal Y; Badawy A; Ali AM; Farghaly HS; Metwalley KA; Gaber N; Allam MT; Farouk Y
    Eur J Pediatr; 2023 Jun; 182(6):2793-2800. PubMed ID: 37022495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.
    Kumeda Y; Inaba M; Tahara H; Kurioka Y; Ishikawa T; Morii H; Nishizawa Y
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4157-61. PubMed ID: 11095447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivated SARS-CoV-2 vaccination does not disturb the clinical course of Graves' disease: An observational cohort study.
    Xu S; Yu H; Cheng X; Wu J; Bao J; Zhang L
    Vaccine; 2023 Aug; 41(38):5648-5654. PubMed ID: 37544826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of Thyroid-Stimulating Immunoglobulin Bioassay and Thyrotropin-Binding Inhibitory Immunoglobulin Assay for the Diagnosis of Graves' Disease in Patients With Active Thyrotoxicosis.
    Silva de Morais N; Angell TE; Ahmadi S; Alexander EK; Dos Santos Teixeira PF; Marqusee E
    Endocr Pract; 2022 May; 28(5):502-508. PubMed ID: 35091101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease.
    Izumi Y; Takeoka K; Amino N
    Endocr J; 2005 Aug; 52(4):493-7. PubMed ID: 16127219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. fT3:fT4 ratio in Graves' disease - correlation with TRAb level, goiter size and age of onset.
    Minasyan M; Dulęba A; Smalarz A; Stręk M; Bryniarski P; Przybylik-Mazurek E; Hubalewska-Dydejczyk A
    Folia Med Cracov; 2020 Sep; 60(2):15-27. PubMed ID: 33252592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
    Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
    Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence of gestational hyperthyroidism and postpartum thyroiditis in treated patients with Graves' disease.
    Tagami T; Hagiwara H; Kimura T; Usui T; Shimatsu A; Naruse M
    Thyroid; 2007 Aug; 17(8):767-72. PubMed ID: 17651013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ratio of serum free triiodothyronine to free thyroxine in Graves' hyperthyroidism and thyrotoxicosis caused by painless thyroiditis.
    Yoshimura Noh J; Momotani N; Fukada S; Ito K; Miyauchi A; Amino N
    Endocr J; 2005 Oct; 52(5):537-42. PubMed ID: 16284430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-21 is associated with disease activity in patients with Graves' disease.
    Zhang J; Zeng H; Ren M; Yan H; Xu M; Feng Z; Liang W; Yang C; Cheng H; Ding H; Yan L
    Endocrine; 2014 Aug; 46(3):539-48. PubMed ID: 24287789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical review: Clinical utility of TSH receptor antibodies.
    Barbesino G; Tomer Y
    J Clin Endocrinol Metab; 2013 Jun; 98(6):2247-55. PubMed ID: 23539719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IGF1 deficiency in newly diagnosed Graves' disease patients.
    Martin S; Sirbu A; Betivoiu M; Florea S; Barbu C; Fica S
    Hormones (Athens); 2015; 14(4):651-9. PubMed ID: 26188228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.